Trial Profile

Testing for the first time the effects of a new medicine in healthy people

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SYT 510 (Primary)
Indications Anxiety disorders; Mood disorders; Neurological disorders; Traumatic stress disorders
Focus Adverse reactions; First in man
Sponsors Synendos Therapeutics

Most Recent Events

27 Jan 2024 New trial record
18 Jan 2024 According to a Synendos Therapeutics media release, the company has received approval from the European Medicines Agency (EMA) to commence the Phase 1 'first-in-human' clinical trial of SYT-510.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com